Related Experiment Video
Updated: Feb 8, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma
Colleen S Curran1, Elad Sharon2
1Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
Abstract:
Disruption of liver immune tolerance allows for the development of autoimmune hepatitis (AIH) and hepatocellular carcinoma (HCC). AIH rarely progresses to HCC but the diseases similarly induce the production of IL-18 and matrix metalloproteinases. These molecules have distinct effects on the immune response, including the programmed cell-death 1 (PD-1) axis. In this review, differences in PD-1 function and possible cell signals in AIH and HCC are highlighted.
Related Concept Videos
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...

